Compare LASR & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LASR | DYN |
|---|---|---|
| Founded | 2000 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.8B |
| IPO Year | 2018 | 2020 |
| Metric | LASR | DYN |
|---|---|---|
| Price | $54.84 | $16.68 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 17 |
| Target Price | $37.86 | ★ $39.94 |
| AVG Volume (30 Days) | 1.3M | ★ 2.1M |
| Earning Date | 02-26-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $227,526,000.00 | N/A |
| Revenue This Year | $31.94 | N/A |
| Revenue Next Year | $11.78 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 12.05 | N/A |
| 52 Week Low | $6.20 | $6.36 |
| 52 Week High | $55.31 | $25.00 |
| Indicator | LASR | DYN |
|---|---|---|
| Relative Strength Index (RSI) | 67.24 | 40.37 |
| Support Level | $41.51 | $16.10 |
| Resistance Level | $55.31 | $17.45 |
| Average True Range (ATR) | 3.73 | 1.01 |
| MACD | 0.65 | -0.07 |
| Stochastic Oscillator | 98.12 | 15.50 |
nLight Inc is a United States-based company provider of power semiconductor and fiber lasers for aerospace and defense, industrial, and microfabrication applications. It designs, manufactures, and sells a range of power semiconductor lasers and fiber lasers that are typically integrated into laser systems. It operates in two segments: Laser Products, which includes semiconductor lasers, fiber lasers, and directed energy products; and Development segment includes revenue earned from research and development contracts. The majority of its revenue is generated from the Laser segment. The company's geographical segments include North America, Asia Pacific, and EMEA.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.